<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-application-publication SYSTEM "pap-v16-2002-01-01.dtd" [
<!ENTITY US20030003145A1-20030102-C00001.CDX SYSTEM "US20030003145A1-20030102-C00001.CDX" NDATA CDX>
<!ENTITY US20030003145A1-20030102-C00001.MOL SYSTEM "US20030003145A1-20030102-C00001.MOL" NDATA MOL>
<!ENTITY US20030003145A1-20030102-C00001.TIF SYSTEM "US20030003145A1-20030102-C00001.TIF" NDATA TIF>
<!ENTITY US20030003145A1-20030102-C00002.CDX SYSTEM "US20030003145A1-20030102-C00002.CDX" NDATA CDX>
<!ENTITY US20030003145A1-20030102-C00002.MOL SYSTEM "US20030003145A1-20030102-C00002.MOL" NDATA MOL>
<!ENTITY US20030003145A1-20030102-C00002.TIF SYSTEM "US20030003145A1-20030102-C00002.TIF" NDATA TIF>
]>
<patent-application-publication>
<subdoc-bibliographic-information>
<document-id>
<doc-number>20030003145</doc-number>
<kind-code>A1</kind-code>
<document-date>20030102</document-date>
</document-id>
<publication-filing-type>new</publication-filing-type>
<domestic-filing-data>
<application-number>
<doc-number>10136148</doc-number>
</application-number>
<application-number-series-code>10</application-number-series-code>
<filing-date>20020501</filing-date>
</domestic-filing-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>97/03835</doc-number>
</priority-application-number>
<filing-date>19970328</filing-date>
<country-code>FR</country-code>
</foreign-priority-data>
<technical-information>
<classification-ipc>
<classification-ipc-primary>
<ipc>A61K031/454</ipc>
</classification-ipc-primary>
<classification-ipc-secondary>
<ipc>A61K009/20</ipc>
</classification-ipc-secondary>
<classification-ipc-edition>07</classification-ipc-edition>
</classification-ipc>
<classification-us>
<classification-us-primary>
<uspc>
<class>424</class>
<subclass>465000</subclass>
</uspc>
</classification-us-primary>
<classification-us-secondary>
<uspc>
<class>514</class>
<subclass>326000</subclass>
</uspc>
</classification-us-secondary>
</classification-us>
<title-of-invention>Pharmaceutical composition for oral administration of a N-piperidino-3- pyrazolecarboxamide derivative, its salts and their solvates</title-of-invention>
</technical-information>
<continuity-data>
<continuations>
<continuation-of>
<parent-child>
<child>
<document-id>
<doc-number>10136148</doc-number>
<kind-code>A1</kind-code>
<document-date>20020501</document-date>
</document-id>
</child>
<parent>
<document-id>
<doc-number>09381706</doc-number>
<document-date>19990922</document-date>
<country-code>US</country-code>
</document-id>
</parent>
<parent-status>ABANDONED</parent-status>
</parent-child>
</continuation-of>
</continuations>
<a-371-of-international>
<parent-child>
<child>
<document-id>
<doc-number>09381706</doc-number>
<document-date>19990922</document-date>
<country-code>US</country-code>
</document-id>
</child>
<parent>
<document-id>
<doc-number>PCT/FR98/00631</doc-number>
<document-date>19980327</document-date>
<country-code>WO</country-code>
</document-id>
</parent>
<parent-status>UNKNOWN</parent-status>
</parent-child>
</a-371-of-international>
</continuity-data>
<inventors>
<first-named-inventor>
<name>
<given-name>Bernard</given-name>
<family-name>Abramovici</family-name>
</name>
<residence>
<residence-non-us>
<city>Juvignac</city>
<country-code>FR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</first-named-inventor>
<inventor>
<name>
<given-name>Christian</given-name>
<family-name>Condamine</family-name>
</name>
<residence>
<residence-non-us>
<city>Fabregues</city>
<country-code>FR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Jean-Claude</given-name>
<family-name>Gromenil</family-name>
</name>
<residence>
<residence-non-us>
<city>Montbazin</city>
<country-code>FR</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
</inventors>
<correspondence-address>
<name-1>SANOFI-SYNTHELABO INC.</name-1>
<name-2></name-2>
<address>
<address-1>9 GREAT VALLEY PARKWAY</address-1>
<address-2>P.O. BOX 3026</address-2>
<city>MALVERN</city>
<state>PA</state>
<postalcode>19355</postalcode>
<country>
<country-code>US</country-code>
</country>
</address>
</correspondence-address>
</subdoc-bibliographic-information>
<subdoc-abstract>
<paragraph id="A-0001" lvl="0">The pharmaceutical compositions for oral administration according to the invention contain 0.5% to 20% of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide in microcrystalline form, and pharmaceutical excipients; they are formulated by wet granulation. </paragraph>
</subdoc-abstract>
<subdoc-description>
<summary-of-invention>
<paragraph id="P-0001" lvl="0"><number>&lsqb;0001&rsqb;</number> The present invention relates to a pharmaceutical composition for the oral administration of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide of the formula  
<chemistry-cwu id="CHEM-US-00001">
<number>1</number>
<image id="EMI-C00001" he="116.88705" wi="168.99435" file="US20030003145A1-20030102-C00001.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00001" file="US20030003145A1-20030102-C00001.CDX"/>
<chemistry-mol-file id="CHEMMOL-00001" file="US20030003145A1-20030102-C00001.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0002" lvl="7"><number>&lsqb;0002&rsqb;</number> its pharmaceutically acceptable salts and their solvates, which are hereafter referred to as compounds of formula (I). </paragraph>
<paragraph id="P-0003" lvl="0"><number>&lsqb;0003&rsqb;</number> The compounds of formula (I) and their method of preparation are described in European patent application EP 656 354. </paragraph>
<paragraph id="P-0004" lvl="0"><number>&lsqb;0004&rsqb;</number> N-Piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, which is also known by the code name SR 141716 and is called compound A in the following description, is very particularly preferred for the pharmaceutical composition according to the present invention. </paragraph>
<paragraph id="P-0005" lvl="0"><number>&lsqb;0005&rsqb;</number> The pharmacological properties of the compounds of formula (I), which are selective antagonists of the CB1 central cannabinoid receptors, have been recorded, especially in the publication of M. Rinaldi-Carmona et al., FEBS Letters, 1994, 240-244. </paragraph>
<paragraph id="P-0006" lvl="0"><number>&lsqb;0006&rsqb;</number> The oral administration of such compounds requires them to have a good absorption, which entails both a good solubility in aqueous media and a good ability to pass through the intestinal membrane (M. Rowland and T. N. Tozer in Clinical Pharmacokinetics, concepts and applications, published by Lea and Fehiger, 1989, 2nd edition, pp. 113-130). </paragraph>
<paragraph id="P-0007" lvl="0"><number>&lsqb;0007&rsqb;</number> The permeability of the epithelium of the compounds is evaluated using the Caco-2 cell line, which has the characteristic of undergoing differentiation in vitro to form an epithelial monolayer (Crit. Rev. Ther. Drug Carrier System, 1991, 8 (4), 105-330). In this model the permeability of compound A dissolved in dimethyl sulfoxide (DMSO) is high, showing that it has a good ability to be absorbed by the intestine when it is in solution. </paragraph>
<paragraph id="P-0008" lvl="0"><number>&lsqb;0008&rsqb;</number> Furthermore, the hydrophobic character of the compounds of formula (I) is very strongly pronounced. Thus it has been observed that compound A is not wettable in water and that this compound and its salts are practically insoluble in water, irrespective of the pH. These compounds are soluble in alcohols and glycols and more particularly in polyethylene glycols (PEG). </paragraph>
<paragraph id="P-0009" lvl="0"><number>&lsqb;0009&rsqb;</number> However, when the solutions obtained with an alcohol or a glycol are diluted in an aqueous medium, the compound of formula (I) precipitates because of its strongly hydrophobic character. </paragraph>
<paragraph id="P-0010" lvl="0"><number>&lsqb;0010&rsqb;</number> The compounds of formula (I), and particularly compound A, are not very electrostatic. Micronization can be carried out with a good yield (about 85%) and affords particles of about 1 micron. Analytical controls performed after micronization show that there is no modification of the crystalline form. </paragraph>
<paragraph id="P-0011" lvl="0"><number>&lsqb;0011&rsqb;</number> On studying the wettability, it was found that the rate of penetration of water into a bed of powder formulated by wet granulation is much higher than that measured in a bed of powder obtained by dry mixing. A study of the effects of incorporating wetting agents showed that a low concentration of a sodium alkylsulfate considerably increases the wettability. </paragraph>
<paragraph id="P-0012" lvl="0"><number>&lsqb;0012&rsqb;</number> It was further found that the presence of a disintegrating agent, such as crosslinked sodium carboxymethyl cellulose, in the formulation makes it possible to improve the kinetics of dissolution. </paragraph>
<paragraph id="P-0013" lvl="0"><number>&lsqb;0013&rsqb;</number> Surprisingly it was found that by associating a sodium alkylsulfate with a disintegrating agent in the same formulation, the formulation dissolves rapidly and completely and with a good reproducibility of the results. </paragraph>
<paragraph id="P-0014" lvl="0"><number>&lsqb;0014&rsqb;</number> Thus, according to one of its aspects, the present invention relates to a pharmaceutical composition for the oral administration of a compound of formula (I), comprising: </paragraph>
<paragraph id="P-0015" lvl="2"><number>&lsqb;0015&rsqb;</number> 0.5% to 20% by weight of a compound of formula (I) in micronized form, </paragraph>
<paragraph id="P-0016" lvl="2"><number>&lsqb;0016&rsqb;</number> 0.05% to 0.5% by weight of a sodium alkylsulfate, </paragraph>
<paragraph id="P-0017" lvl="2"><number>&lsqb;0017&rsqb;</number> 2.5% to 10% by weight of disintegrating agent, </paragraph>
<paragraph id="P-0018" lvl="7"><number>&lsqb;0018&rsqb;</number> and pharmaceutical excipients, said composition being formulated by wet granulation. </paragraph>
<paragraph id="P-0019" lvl="0"><number>&lsqb;0019&rsqb;</number> Wet granulation is understood as meaning the pharmaceutical operation by which a mixture of powders containing the active principle can be densified with the aid of a granulating liquid, said mixture constituting the internal phase of the formulation, the resulting wet mass being dried and then graded before the ingredients constituting the external phase of said formulation are added. </paragraph>
<paragraph id="P-0020" lvl="0"><number>&lsqb;0020&rsqb;</number> According to the present invention, sodium alkylsulfate is understood as meaning a sodium (C<highlight><subscript>8</subscript></highlight>-C<highlight><subscript>12</subscript></highlight>)alkylsulfate, for example sodium octylsulfate or, preferably, sodium laurylsulfate. </paragraph>
<paragraph id="P-0021" lvl="0"><number>&lsqb;0021&rsqb;</number> According to the present invention, disintegrating agent is understood as meaning cellulose or cellulose derivatives such as sodium carboxymethyl cellulose or crosslinked sodium carboxymethyl cellulose, crospovidone, pregelatinized starch or sodium carboxymethyl starch, crosslinked sodium carboxymethyl cellulose being a preferred disintegrating agent. </paragraph>
<paragraph id="P-0022" lvl="0"><number>&lsqb;0022&rsqb;</number> The pharmaceutical compositions according to the present invention can be presented in the form of gelatin capsules, tablets, sachets or powders, preferably in the form of gelatin capsules. </paragraph>
<paragraph id="P-0023" lvl="0"><number>&lsqb;0023&rsqb;</number> The pharmaceutical excipients which can be used for the pharmaceutical composition according to the present invention include especially a diluent, a binder and a lubricant. A flowing agent, an antiadhesive and, optionally, a coloring agent and/or a flavoring agent can also be added. </paragraph>
<paragraph id="P-0024" lvl="0"><number>&lsqb;0024&rsqb;</number> The diluent used in the composition of the present invention can be one or more compounds which are capable of densifying the active principle to give the desired mass. The preferred diluents are inorganic phosphates such as calcium phosphates; sugars such as hydrated or anhydrous lactose, or mannitol; and cellulose or cellulose derivatives such as, for example, microcrystalline cellulose, starch, corn starch or pregelatinized starch. Lactose monohydrate, mannitol, microcrystalline cellulose and corn starch, used by themselves or in a mixture, for example a mixture of lactose monohydrate and corn starch, are very particularly preferred. </paragraph>
<paragraph id="P-0025" lvl="0"><number>&lsqb;0025&rsqb;</number> The binder employed in the composition of the present invention can be one or more compounds which are capable of densifying a compound of formula (I) by converting it to larger and denser particles with better flow properties. The preferred binders are alginic acid or sodium alginate; cellulose and cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or methyl cellulose; gelatin; acrylic acid polymers; and povidone, for example povidone K 30, which is a very particularly preferred binder. The binder is present in a proportion of 1% to 10% by weight in the pharmaceutical composition according to the invention. </paragraph>
<paragraph id="P-0026" lvl="0"><number>&lsqb;0026&rsqb;</number> The lubricant employed in the composition of the present invention can be one or more compounds which are capable of preventing the problems associated with the preparation of dry forms, such as the sticking and/or seizing problems which occur in the machines during compression or filling. The preferred lubricants are fatty acids or fatty acid derivatives such as calcium stearate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, sodium laurylsulfate, sodium stearylfumarate, zinc stearate or stearic acid; hydrogenated vegetable oils, for example hydrogenated castor oil; polyalkylene glycols, especially polyethylene glycol; sodium benzoate; or talcum. Magnesium stearate is preferred according to the present invention. The lubricant is present in a proportion of 0.2% to 5% by weight in the pharmaceutical composition according to the invention. </paragraph>
<paragraph id="P-0027" lvl="0"><number>&lsqb;0027&rsqb;</number> The antiadhesive which may be employed in the composition of the present invention can be one or more compounds which are capable of reducing the sticky character of the formulation, for example of preventing adhesion to metal surfaces. The preferred antiadhesives are compounds containing silicon, for example silica or talcum. The antiadhesive can be present in a proportion of 0 to 5% by weight in the pharmaceutical composition according to the invention. </paragraph>
<paragraph id="P-0028" lvl="0"><number>&lsqb;0028&rsqb;</number> The flowing agent which may be employed in the composition of the present invention can be one or more compounds which are capable of facilitating the flow of the prepared formulation. The preferred flowing agents are compounds containing silicon, for example anhydrous colloidal silica or precipitated silica. The flowing agent can be present in a proportion of 0 to 15% by weight in the pharmaceutical composition according to the invention. </paragraph>
<paragraph id="P-0029" lvl="0"><number>&lsqb;0029&rsqb;</number> According to the present invention, the pharmaceutical compositions are prepared by a wet granulation process. Thus, for the internal phase, the active principle, the diluent, the binder, the disintegrating agent, the sodium alkylsulfate and, optionally, the coloring agent are mixed at room temperature and then wetted with the granulating liquid. The wet mass obtained is dried and then graded. The ingredient or ingredients of the external phase, namely the lubricant, possibly the antiadhesive, the flowing agent and, if appropriate, the coloring agent and/or the flavoring agent, are then added to the graded dry grains. </paragraph>
<paragraph id="P-0030" lvl="0"><number>&lsqb;0030&rsqb;</number> Purified water is used as the granulating liquid. </paragraph>
<paragraph id="P-0031" lvl="0"><number>&lsqb;0031&rsqb;</number> In one preferred embodiment, the sodium alkylsulfate is added to the purified water in order to carry out the wet granulation. </paragraph>
<paragraph id="P-0032" lvl="0"><number>&lsqb;0032&rsqb;</number> In particular, the present invention relates to a pharmaceutical composition for oral administration which comprises: </paragraph>
<paragraph id="P-0033" lvl="2"><number>&lsqb;0033&rsqb;</number> 0.5% to 20% by weight of compound A in micronized form, </paragraph>
<paragraph id="P-0034" lvl="2"><number>&lsqb;0034&rsqb;</number> 0.05% to 0.5% by weight of sodium laurylsulfate, </paragraph>
<paragraph id="P-0035" lvl="2"><number>&lsqb;0035&rsqb;</number> 2.5% to 10% by weight of crosslinked sodium carboxymethyl cellulose, </paragraph>
<paragraph id="P-0036" lvl="7"><number>&lsqb;0036&rsqb;</number> and pharmaceutical excipients, said composition being formulated by wet granulation. </paragraph>
<paragraph id="P-0037" lvl="0"><number>&lsqb;0037&rsqb;</number> Preferably the present invention relates to a pharmaceutical composition for oral administration which is formulated by wet granulation and which contains: </paragraph>
<paragraph id="P-0038" lvl="2"><number>&lsqb;0038&rsqb;</number> 0.5% to 20% by weight of compound A in micronized form, </paragraph>
<paragraph id="P-0039" lvl="2"><number>&lsqb;0039&rsqb;</number> 0.1% by weight of sodium laurylsulfate, </paragraph>
<paragraph id="P-0040" lvl="2"><number>&lsqb;0040&rsqb;</number> 5% by weight of crosslinked sodium carboxymethyl cellulose, </paragraph>
<paragraph id="P-0041" lvl="2"><number>&lsqb;0041&rsqb;</number> 1% to 10% by weight of binder, </paragraph>
<paragraph id="P-0042" lvl="2"><number>&lsqb;0042&rsqb;</number> 0.2% to 5% by weight of lubricant, </paragraph>
<paragraph id="P-0043" lvl="7"><number>&lsqb;0043&rsqb;</number> and a diluent in sufficient amount for 100%. </paragraph>
<paragraph id="P-0044" lvl="0"><number>&lsqb;0044&rsqb;</number> Very particularly, the present invention relates to pharmaceutical compositions in the form of gelatin capsules which are prepared by wet granulation and which have one of the following formulations, expressed in percentages by weight:  
<table-cwu id="TABLE-US-00001">
<number>1</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="133PT" align="left"/>
<colspec colname="2" colwidth="70PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>i) Internal phase</entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>micronized compound A</entry>
<entry>0.59%</entry>
</row>
<row>
<entry></entry>
<entry>corn starch</entry>
<entry>30%&thinsp;&emsp;&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>200 mesh lactose monohydrate</entry>
<entry>60.78%&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>povidone K 30</entry>
<entry>2.53%</entry>
</row>
<row>
<entry></entry>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>5%&thinsp;&emsp;</entry>
</row>
<row>
<entry></entry>
<entry>Granulation</entry>
</row>
<row>
<entry></entry>
<entry>sodium laurylsulfate</entry>
<entry>0.1%&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry></entry>
<entry>External phase</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>1%&thinsp;&emsp;</entry>
</row>
<row>
<entry></entry>
<entry>ii) Internal phase</entry>
</row>
<row>
<entry></entry>
<entry>micronized compound A</entry>
<entry>5.88%</entry>
</row>
<row>
<entry></entry>
<entry>corn starch</entry>
<entry>30%&thinsp;&emsp;&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>200 mesh lactose monohydrate</entry>
<entry>55.49%&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>povidone K 30</entry>
<entry>2.53%</entry>
</row>
<row>
<entry></entry>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>5%&thinsp;&emsp;</entry>
</row>
<row>
<entry></entry>
<entry>Granulation</entry>
</row>
<row>
<entry></entry>
<entry>sodium laurylsulfate</entry>
<entry>0.1%&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry></entry>
<entry>External phase</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>1%&thinsp;&emsp;</entry>
</row>
<row>
<entry></entry>
<entry>iii) Internal phase</entry>
</row>
<row>
<entry></entry>
<entry>micronized compound A</entry>
<entry>17.64%&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>corn starch</entry>
<entry>30%&thinsp;&emsp;&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>200 mesh lactose monohydrate</entry>
<entry>43.73%&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>povidone K 30</entry>
<entry>2.53%</entry>
</row>
<row>
<entry></entry>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>5%&thinsp;&emsp;</entry>
</row>
<row>
<entry></entry>
<entry>Granulation</entry>
</row>
<row>
<entry></entry>
<entry>sodium laurylsulfate</entry>
<entry>0.1%&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry></entry>
<entry>External phase</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>1%&thinsp;&emsp;</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0045" lvl="0"><number>&lsqb;0045&rsqb;</number> The characteristics and advantages of the compositions according to the invention will become appear in the light of the following description, from the compositions given as Examples. </paragraph>
<paragraph id="P-0046" lvl="7"><number>&lsqb;0046&rsqb;</number> Tests </paragraph>
<paragraph id="P-0047" lvl="0"><number>&lsqb;0047&rsqb;</number> 1. Study of the solubility of the compounds of formula (I) </paragraph>
<paragraph id="P-0048" lvl="0"><number>&lsqb;0048&rsqb;</number> The solubilities of the compounds of formula (I) are measured in different aqueous media. The instantaneous solubility is evaluated at room temperature by quantitative analysis. The results, expressed in &mgr;g per ml, are collated in Table 1 below:  
<table-cwu id="TABLE-US-00002">
<number>2</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="OFFSET" colwidth="91PT" align="left"/>
<colspec colname="1" colwidth="126PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center">TABLE 1</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Dissolution medium</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="91PT" align="left"/>
<colspec colname="2" colwidth="28PT" align="center"/>
<colspec colname="3" colwidth="28PT" align="center"/>
<colspec colname="4" colwidth="35PT" align="center"/>
<colspec colname="5" colwidth="35PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
<entry>Water &plus;</entry>
<entry>Acetic</entry>
<entry>Phosphate</entry>
</row>
<row>
<entry>Compound of</entry>
<entry></entry>
<entry>10%</entry>
<entry>buffer</entry>
<entry>buffer</entry>
</row>
<row>
<entry>formula (I)</entry>
<entry>Water</entry>
<entry>ethanol</entry>
<entry>pH 7.5</entry>
<entry>pH 7.5</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="91PT" align="left"/>
<colspec colname="2" colwidth="28PT" align="char" char="."/>
<colspec colname="3" colwidth="28PT" align="char" char="."/>
<colspec colname="4" colwidth="35PT" align="char" char="."/>
<colspec colname="5" colwidth="35PT" align="center"/>
<tbody valign="top">
<row>
<entry>Compound A (base)</entry>
<entry>1</entry>
<entry>1.2</entry>
<entry>1.9</entry>
<entry>1.6</entry>
</row>
<row>
<entry>Hydrochloride (solvated)</entry>
<entry>37</entry>
<entry>10</entry>
<entry>54</entry>
<entry>0.5</entry>
</row>
<row>
<entry>Methanesulfonate (solvated)</entry>
<entry>39</entry>
<entry>48</entry>
<entry>54</entry>
<entry>0.9</entry>
</row>
<row>
<entry>Hydrogensulfate</entry>
<entry>13</entry>
<entry>38</entry>
<entry>30</entry>
<entry>0.9</entry>
</row>
<row>
<entry>Paratoluenesulfonate</entry>
<entry>3.9</entry>
<entry>7.3</entry>
<entry>2.4</entry>
<entry>0.2</entry>
</row>
<row>
<entry>Phosphate</entry>
<entry>1.3</entry>
<entry>7.5</entry>
<entry>0.9</entry>
<entry>0.7</entry>
</row>
<row>
<entry>Solvated compound A</entry>
<entry>0.7</entry>
<entry>0.9</entry>
<entry>1.2</entry>
<entry>0.9</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0049" lvl="0"><number>&lsqb;0049&rsqb;</number> Measurements were also made of the solubility of compound A in different solvents (Table 2) and after dilution in water of the solutions formed (Table 3).  
<table-cwu id="TABLE-US-00003">
<number>3</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="105PT" align="left"/>
<colspec colname="2" colwidth="98PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center">TABLE 2</entry>
</row>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Solvent</entry>
<entry>Solubility of compound A</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>Ethanol</entry>
<entry>35 mg/ml</entry>
</row>
<row>
<entry></entry>
<entry>Polyethylene glycol 400</entry>
<entry>50 mg/ml</entry>
</row>
<row>
<entry></entry>
<entry>Polyethylene glycol 1500 at 60&deg; C.</entry>
<entry>80 mg/g&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0050" lvl="0"><number>&lsqb;0050&rsqb;</number>  
<table-cwu id="TABLE-US-00004">
<number>4</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="OFFSET" colwidth="49PT" align="left"/>
<colspec colname="1" colwidth="42PT" align="center"/>
<colspec colname="2" colwidth="42PT" align="center"/>
<colspec colname="3" colwidth="84PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center">TABLE 3</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry>Amount of compound A</entry>
</row>
<row>
<entry></entry>
<entry>Solubility of</entry>
<entry>Dilution in</entry>
<entry>dissolved</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="49PT" align="left"/>
<colspec colname="2" colwidth="42PT" align="center"/>
<colspec colname="3" colwidth="42PT" align="center"/>
<colspec colname="4" colwidth="35PT" align="center"/>
<colspec colname="5" colwidth="49PT" align="center"/>
<tbody valign="top">
<row>
<entry>Solvent</entry>
<entry>compound A</entry>
<entry>water</entry>
<entry>theoretical</entry>
<entry>measured</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Ethanol</entry>
<entry>35 mg/ml</entry>
<entry>10%</entry>
<entry>3.5 mg/ml</entry>
<entry>1.2.10<highlight><superscript>&minus;3 </superscript></highlight>mg/ml</entry>
</row>
<row>
<entry>Polyethylene</entry>
<entry>50 mg/ml</entry>
<entry>30%</entry>
<entry>&thinsp;15 mg/ml</entry>
<entry>&ensp;&thinsp;3.10<highlight><superscript>&minus;3 </superscript></highlight>mg/ml</entry>
</row>
<row>
<entry>glycol 400</entry>
</row>
<row>
<entry>Polyethylene</entry>
<entry>80 mg/g&thinsp;</entry>
<entry>not dilutable</entry>
</row>
<row>
<entry>glycol</entry>
</row>
<row>
<entry>1500 at 60&deg; C.</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0051" lvl="0"><number>&lsqb;0051&rsqb;</number> 2. Study of the Wettability </paragraph>
<paragraph id="P-0052" lvl="0"><number>&lsqb;0052&rsqb;</number> The wettability of compound A was studied in different formulations using the method of H. Mohamad et al., Labo Pharma. Probl&egrave;mes techniques, 1984, 32 (346), 284-289. </paragraph>
<paragraph id="P-0053" lvl="0"><number>&lsqb;0053&rsqb;</number> 2.1. Influence of the granulation process </paragraph>
<paragraph id="P-0054" lvl="0"><number>&lsqb;0054&rsqb;</number> A formulation obtained by simple mixing (formulation 1) was compared with a formulation obtained by wet granulation (formulation 2).  
<table-cwu id="TABLE-US-00005">
<number>5</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="OFFSET" colwidth="21PT" align="left"/>
<colspec colname="1" colwidth="126PT" align="left"/>
<colspec colname="2" colwidth="70PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>Formulation 1</entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>compound A</entry>
<entry>30 mg</entry>
</row>
<row>
<entry></entry>
<entry>modified corn starch</entry>
<entry>48 mg</entry>
</row>
<row>
<entry></entry>
<entry>extrafine crystals of lactose monohydrate</entry>
<entry>70.1 mg&ensp;&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>anhydrous colloidal silica</entry>
<entry>0.4 mg&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>1.5 mg&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>Gelatin capsule</entry>
<entry>150 mg&ensp;</entry>
</row>
<row>
<entry></entry>
<entry>Formulation 2</entry>
</row>
<row>
<entry></entry>
<entry>compound A</entry>
<entry>30 mg</entry>
</row>
<row>
<entry></entry>
<entry>modified corn starch</entry>
<entry>51 mg</entry>
</row>
<row>
<entry></entry>
<entry>200 mesh lactose monohydrate</entry>
<entry>83 mg</entry>
</row>
<row>
<entry></entry>
<entry>povidone K 30</entry>
<entry>4.3 mg&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>1.7 mg&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>Gelatin capsule</entry>
<entry>170 mg&ensp;</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0055" lvl="0"><number>&lsqb;0055&rsqb;</number> The wettability measured according to H. Mohamad&apos;s method is 22 mg<highlight><superscript>2</superscript></highlight>/s for formulation 1 and 10 mg<highlight><superscript>2</superscript></highlight>/s for formulation 2. </paragraph>
<paragraph id="P-0056" lvl="0"><number>&lsqb;0056&rsqb;</number> Thus the wet granulation process improves the wettability by a factor of 5. </paragraph>
<paragraph id="P-0057" lvl="0"><number>&lsqb;0057&rsqb;</number> 2.2. Influence of the active principle content </paragraph>
<paragraph id="P-0058" lvl="0"><number>&lsqb;0058&rsqb;</number> For comparison purposes, formulations in which the active principle content was respectively 10 mg (formulation 3) and 1 mg (formulation 4) were prepared by wet granulation.  
<table-cwu id="TABLE-US-00006">
<number>6</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="OFFSET" colwidth="105PT" align="left"/>
<colspec colname="1" colwidth="49PT" align="center"/>
<colspec colname="2" colwidth="63PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center">TABLE 4</entry>
</row>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Formulation 3</entry>
<entry>Formulation 4</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="105PT" align="left"/>
<colspec colname="2" colwidth="49PT" align="center"/>
<colspec colname="3" colwidth="63PT" align="center"/>
<tbody valign="top">
<row>
<entry>compound A</entry>
<entry>&ensp;10 mg</entry>
<entry>&emsp;1 mg</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>&ensp;51 mg</entry>
<entry>&ensp;51 mg</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>103 mg</entry>
<entry>112 mg</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>&thinsp;4.3 mg</entry>
<entry>&thinsp;4.3 mg</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>&thinsp;1.7 mg</entry>
<entry>&thinsp;1.7 mg</entry>
</row>
<row>
<entry>Gelatin capsule</entry>
<entry>170 mg</entry>
<entry>170 mg</entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0059" lvl="0"><number>&lsqb;0059&rsqb;</number> The wettability is 500 mg<highlight><superscript>2</superscript></highlight>/s for formulation3. </paragraph>
<paragraph id="P-0060" lvl="0"><number>&lsqb;0060&rsqb;</number> The wettability is 1000 mg<highlight><superscript>2</superscript></highlight>/s for formulation 4. </paragraph>
<paragraph id="P-0061" lvl="0"><number>&lsqb;0061&rsqb;</number> Thus the wettability is inversely proportional to the amount of active principle contained in the formulation. This illustrates the hydrophobic character of compound A. </paragraph>
<paragraph id="P-0062" lvl="0"><number>&lsqb;0062&rsqb;</number> 2.3. Influence of the excipients </paragraph>
<paragraph id="P-0063" lvl="0"><number>&lsqb;0063&rsqb;</number> Several formulations were prepared by wet granulation and compared with a reference formulation also obtained by wet granulation.  
<table-cwu id="TABLE-US-00007">
<number>7</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="OFFSET" colwidth="84PT" align="left"/>
<colspec colname="1" colwidth="133PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center">TABLE 5</entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry>Formulation</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="OFFSET" colwidth="105PT" align="left"/>
<colspec colname="1" colwidth="28PT" align="center"/>
<colspec colname="2" colwidth="28PT" align="center"/>
<colspec colname="3" colwidth="28PT" align="center"/>
<colspec colname="4" colwidth="28PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>4</entry>
<entry>5</entry>
<entry>6</entry>
<entry>7</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="84PT" align="left"/>
<colspec colname="2" colwidth="21PT" align="char" char="."/>
<colspec colname="3" colwidth="28PT" align="char" char="."/>
<colspec colname="4" colwidth="28PT" align="char" char="."/>
<colspec colname="5" colwidth="28PT" align="char" char="."/>
<colspec colname="6" colwidth="28PT" align="char" char="."/>
<tbody valign="top">
<row>
<entry>compound A</entry>
<entry>30</entry>
<entry>30</entry>
<entry>30</entry>
<entry>30</entry>
<entry>30</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>51</entry>
<entry>51</entry>
<entry>51</entry>
<entry>51</entry>
<entry>51</entry>
</row>
<row>
<entry>200 mesh lactose</entry>
<entry>83</entry>
<entry>83</entry>
<entry>83</entry>
<entry>83</entry>
<entry>83</entry>
</row>
<row>
<entry>monohydrate</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>4.3</entry>
<entry>4.3</entry>
<entry>4.3</entry>
<entry>4.3</entry>
<entry>4.3</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry></entry>
<entry>0.17</entry>
<entry>0.85</entry>
</row>
<row>
<entry>polyethylene glycol 6000</entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry>1.7</entry>
<entry>8.5</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry></entry>
<entry>1.7</entry>
<entry>1.7</entry>
<entry>1.7</entry>
<entry>1.7</entry>
</row>
<row>
<entry>wettability</entry>
<entry>600</entry>
<entry>1200</entry>
<entry>2300</entry>
<entry>1100</entry>
<entry>1100</entry>
</row>
<row>
<entry>mg<highlight><superscript>2</superscript></highlight>/s</entry>
<entry>&plusmn;150</entry>
<entry>&plusmn;300</entry>
<entry>&plusmn;300</entry>
<entry>&plusmn;200</entry>
<entry>&plusmn;200</entry>
</row>
<row><entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0064" lvl="0"><number>&lsqb;0064&rsqb;</number> Only 0.5% sodium laurylsulfate improves the wettability significantly. </paragraph>
<paragraph id="P-0065" lvl="0"><number>&lsqb;0065&rsqb;</number> The wettability measurements are not suitable for studying the effect of a disintegrating agent like crosslinked sodium carboxymethyl cellulose. </paragraph>
<paragraph id="P-0066" lvl="0"><number>&lsqb;0066&rsqb;</number> 3. Study of the dissolution in a gastric medium </paragraph>
<paragraph id="P-0067" lvl="0"><number>&lsqb;0067&rsqb;</number> The kinetics of dissolution of different formulations in a gastric medium were studied at 37&deg; C. in a phosphate-citrate buffer of pH 3 for 30 minutes. </paragraph>
<paragraph id="P-0068" lvl="0"><number>&lsqb;0068&rsqb;</number> When 40 mg of compound A are placed in one liter of the dissolution medium with nothing else added, it is observed that no dissolution takes place. </paragraph>
<paragraph id="P-0069" lvl="0"><number>&lsqb;0069&rsqb;</number> To enable dissolution of the test formulations, 0.2% of sodium laurylsulfate was added to the medium as a surfactant.  
<table-cwu id="TABLE-US-00008">
<number>8</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="77PT" align="left"/>
<colspec colname="2" colwidth="35PT" align="left"/>
<colspec colname="3" colwidth="35PT" align="left"/>
<colspec colname="4" colwidth="35PT" align="left"/>
<colspec colname="5" colwidth="35PT" align="left"/>
<thead>
<row>
<entry namest="1" nameend="5" align="center">TABLE 6</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>A</entry>
<entry>B</entry>
<entry>C</entry>
<entry>D</entry>
</row>
<row>
<entry>Formulation</entry>
<entry>mg</entry>
<entry>mg</entry>
<entry>mg</entry>
<entry>mg</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Internal phase</entry>
</row>
<row>
<entry>compound A</entry>
<entry>&ensp;30.0</entry>
<entry>&ensp;30.0</entry>
<entry>&ensp;30.0</entry>
<entry>&ensp;30.0</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>&ensp;51.0</entry>
<entry>&ensp;51.0</entry>
<entry>&ensp;51.0</entry>
<entry>&ensp;51.0</entry>
</row>
<row>
<entry>200 mesh lactose</entry>
<entry>&ensp;83.0</entry>
<entry>&ensp;83.0</entry>
<entry>&ensp;83.0</entry>
<entry>&ensp;83.0</entry>
</row>
<row>
<entry>monohydrate</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>&emsp;4.3</entry>
<entry>&emsp;4.3</entry>
<entry>&emsp;4.3</entry>
<entry>&emsp;4.3</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry>&emsp;0.17</entry>
<entry>&emsp;0.85</entry>
</row>
<row>
<entry>polyethylene glycol 6000</entry>
<entry></entry>
<entry></entry>
<entry>&emsp;1.7</entry>
<entry>&emsp;8.5</entry>
</row>
<row>
<entry>crosslinked sodium</entry>
</row>
<row>
<entry>carboxymethyl cellulose</entry>
</row>
<row>
<entry>purified water for wetting</entry>
<entry>QS</entry>
<entry>QS</entry>
<entry>QS</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>&emsp;1.7</entry>
<entry>&emsp;1.7</entry>
<entry>&emsp;1.7</entry>
<entry>&emsp;1.7</entry>
</row>
<row>
<entry>content of the</entry>
<entry>170.17 mg</entry>
<entry>170.85 mg</entry>
<entry>171.7 mg</entry>
<entry>178.5 mg</entry>
</row>
<row>
<entry>gelatin capsule</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="105PT" align="left"/>
<colspec colname="2" colwidth="35PT" align="left"/>
<colspec colname="3" colwidth="42PT" align="left"/>
<colspec colname="4" colwidth="35PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>E</entry>
<entry>F</entry>
<entry>G</entry>
</row>
<row>
<entry>Formulation</entry>
<entry>mg</entry>
<entry>mg</entry>
<entry>mg</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Internal phase</entry>
</row>
<row>
<entry>compound A</entry>
<entry>&ensp;30.0</entry>
<entry>&ensp;30.0</entry>
<entry>&ensp;30.0</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>&ensp;51.0</entry>
<entry>&ensp;51.0</entry>
<entry>&ensp;51.0</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>&ensp;83.0</entry>
<entry>&ensp;83.0</entry>
<entry>&ensp;83.0</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>&emsp;4.3</entry>
<entry>&emsp;4.3</entry>
<entry>&emsp;4.3</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry></entry>
<entry>&emsp;0.17</entry>
</row>
<row>
<entry>polyethylene glycol 6000</entry>
</row>
<row>
<entry>crosslinked sodium</entry>
<entry>&emsp;8.5</entry>
<entry>&emsp;8.5</entry>
<entry>&emsp;4.25</entry>
</row>
<row>
<entry>carboxymethyl cellulose</entry>
</row>
<row>
<entry>purified water for wetting</entry>
<entry>QS</entry>
<entry>QS</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>&emsp;1.7</entry>
<entry>&emsp;1.7</entry>
<entry>&emsp;1.7</entry>
</row>
<row>
<entry>content of the gelatin capsule</entry>
<entry>178.5 mg</entry>
<entry>178.67 mg</entry>
<entry>174.25 mg</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0070" lvl="0"><number>&lsqb;0070&rsqb;</number> 6 tests were carried out for each formulation and the amount of compound A dissolved in the medium was measured every 5 minutes. </paragraph>
<paragraph id="P-0071" lvl="0"><number>&lsqb;0071&rsqb;</number> Table 7 indicates the mean value of the percentage of compound A dissolved and the standard deviation relative to this value for the different formulations described in Table 6.  
<table-cwu id="TABLE-US-00009">
<number>9</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="28PT" align="center"/>
<colspec colname="2" colwidth="189PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="2" align="center">TABLE 7</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Time in</entry>
<entry>Compound A dissolved in % (standard deviation)</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="28PT" align="center"/>
<colspec colname="2" colwidth="49PT" align="center"/>
<colspec colname="3" colwidth="49PT" align="center"/>
<colspec colname="4" colwidth="49PT" align="center"/>
<colspec colname="5" colwidth="42PT" align="center"/>
<tbody valign="top">
<row>
<entry>minutes</entry>
<entry>A</entry>
<entry>B</entry>
<entry>C</entry>
<entry>D</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry>&ensp;5</entry>
<entry>&emsp;63.4 (12.8)</entry>
<entry>&ensp;63.5 (24.6)</entry>
<entry>56.3 (20.1)</entry>
<entry>61.9 (17.0)</entry>
</row>
<row>
<entry>10</entry>
<entry>&emsp;87.9 (13.6)</entry>
<entry>&ensp;87.6 (13.5)</entry>
<entry>76.2 (15.6)</entry>
<entry>74.7 (15.6)</entry>
</row>
<row>
<entry>15</entry>
<entry>&ensp;97.6 (7.9)</entry>
<entry>94.6 (9.7)</entry>
<entry>86.9 (13.5)</entry>
<entry>81.6 (16.0)</entry>
</row>
<row>
<entry>20</entry>
<entry>100.7 (5.4)</entry>
<entry>96.6 (7.7)</entry>
<entry>93.8 (11.3)</entry>
<entry>88.1 (16.0)</entry>
</row>
<row>
<entry>25</entry>
<entry>102.1 (4.2)</entry>
<entry>98.6 (5.6)</entry>
<entry>97.8 (7.7)&ensp;</entry>
<entry>92.1 (15.2)</entry>
</row>
<row>
<entry>30</entry>
<entry>103.0 (3.2)</entry>
<entry>99.8 (3.7)</entry>
<entry>100.2 (5.1)&emsp;</entry>
<entry>94.8 (14.2)</entry>
</row>
<row><entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="OFFSET" colwidth="56PT" align="left"/>
<colspec colname="1" colwidth="161PT" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>Compound A dissolved in % (standard deviation)</entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="56PT" align="center"/>
<colspec colname="2" colwidth="63PT" align="center"/>
<colspec colname="3" colwidth="42PT" align="center"/>
<colspec colname="4" colwidth="56PT" align="center"/>
<tbody valign="top">
<row>
<entry>Time in minutes</entry>
<entry>E</entry>
<entry>F</entry>
<entry>G</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry>&ensp;5</entry>
<entry>&ensp;62.1 (8.5)</entry>
<entry>&ensp;64.9 (6.4)</entry>
<entry>&ensp;69.8 (7.2)</entry>
</row>
<row>
<entry>10</entry>
<entry>&emsp;85.9 (10.0)</entry>
<entry>&ensp;96.7 (4.5)</entry>
<entry>&ensp;95.4 (8.8)</entry>
</row>
<row>
<entry>15</entry>
<entry>&ensp;97.6 (5.9)</entry>
<entry>&ensp;99.8 (2.3)</entry>
<entry>100.4 (5.2)</entry>
</row>
<row>
<entry>20</entry>
<entry>100.9 (2.8)</entry>
<entry>100.7 (2.1)</entry>
<entry>102.8 (2.8)</entry>
</row>
<row>
<entry>25</entry>
<entry>101.6 (2.7)</entry>
<entry>101.3 (1.9)</entry>
<entry>103.8 (1.7)</entry>
</row>
<row>
<entry>30</entry>
<entry>102.1 (2.8)</entry>
<entry>101.7 (1.5)</entry>
<entry>104.2 (1.6)</entry>
</row>
<row><entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0072" lvl="0"><number>&lsqb;0072&rsqb;</number> For formulations C and D, which respectively contain 1% and 5% of polyethylene glycol 6000, it is found that the maximum dissolution is only reached after 30 minutes. </paragraph>
<paragraph id="P-0073" lvl="0"><number>&lsqb;0073&rsqb;</number> For formulations A and B, which respectively contain 0.1% and 0.5% of sodium laurylsulfate, it is observed that the maximum value is reached after 20 minutes and 30 minutes respectively. </paragraph>
<paragraph id="P-0074" lvl="0"><number>&lsqb;0074&rsqb;</number> Also, the measured results are scattered for each of formulations A, B, C and D. </paragraph>
<paragraph id="P-0075" lvl="0"><number>&lsqb;0075&rsqb;</number> The results observed with formulations E, F and G show the value of the presence of crosslinked sodium carboxymethyl cellulose in promoting the dissolution. </paragraph>
<paragraph id="P-0076" lvl="0"><number>&lsqb;0076&rsqb;</number> For formulations E and G, which respectively contain 5% and 2.5% of crosslinked sodium carboxymethyl cellulose, it is observed that 100% of compound A is dissolved after 20 minutes or 15 minutes respectively, and that the results are relatively scattered in the first 15 minutes. </paragraph>
<paragraph id="P-0077" lvl="0"><number>&lsqb;0077&rsqb;</number> Formulation F, which contains both 0.1% of sodium laurylsulfate and 5% of crosslinked sodium carboxymethyl cellulose, gives the best results. In fact, compound A is totally dissolved after 15 minutes; furthermore, the deviation between the results of the different tests is very low (deviation of 2.3 to 1.5 between 15 and 30 minutes). </paragraph>
<paragraph id="P-0078" lvl="0"><number>&lsqb;0078&rsqb;</number> 5. Evaluation of the intestinal transepithelial passage of compound A </paragraph>
<paragraph id="P-0079" lvl="0"><number>&lsqb;0079&rsqb;</number> Caco-2 cells are cultured onto microporous polycarbonate filters covered with collagen. The cellular monolayer formed on the filter then makes it possible to separate an apical compartment (imitating the intestinal lumen) from a basal compartment (imitating the blood circulation). </paragraph>
<paragraph id="P-0080" lvl="0"><number>&lsqb;0080&rsqb;</number> The composition containing the compound to be studied is placed on the apical side and the passage of this compound, dispersed or solubilized in Hank&apos;s medium, through this cellular barrier is evaluated by measuring the kinetics of its appearance on the basal side. This aqueous medium, of pH 6.5, has the following composition: NaCl&equals;8.0 g/l; KCl&equals;0.4 g/l; CaCl<highlight><subscript>2</subscript></highlight>&equals;0.19 g/l; MgCl<highlight><subscript>2</subscript></highlight>&equals;0.1 g/l; MgSO<highlight><subscript>4</subscript></highlight>&equals;0.1 g/l; Na<highlight><subscript>2</subscript></highlight>HPO<highlight><subscript>4</subscript></highlight>&equals;0.09 g/l; KH<highlight><subscript>2</subscript></highlight>PO<highlight><subscript>4</subscript></highlight>&equals;0.06 g/l; NaHCO<highlight><subscript>3</subscript></highlight>&equals;0.35 g/l; glucose&equals;1 g/l; phenol red&equals;0.01 g/l. </paragraph>
<paragraph id="P-0081" lvl="0"><number>&lsqb;0081&rsqb;</number> The coefficient of permeability P, in cm/s, is then determined; this characterizes the rate of passage of the molecule through the membrane, namely: </paragraph>
<paragraph id="P-0082" lvl="2"><number>&lsqb;0082&rsqb;</number> P&equals;(da/dt).(1/A.Co) </paragraph>
<paragraph id="P-0083" lvl="7"><number>&lsqb;0083&rsqb;</number> where: </paragraph>
<paragraph id="P-0084" lvl="2"><number>&lsqb;0084&rsqb;</number> da/dt&equals;variation of the amount of test compound passing through the cellular monolayer as a function of time (mol/s) </paragraph>
<paragraph id="P-0085" lvl="2"><number>&lsqb;0085&rsqb;</number> A&equals;surface area of the monolayer (cm<highlight><superscript>2</superscript></highlight>) </paragraph>
<paragraph id="P-0086" lvl="2"><number>&lsqb;0086&rsqb;</number> Co&equals;initial concentration of the test compound (mol/l) </paragraph>
<paragraph id="P-0087" lvl="0"><number>&lsqb;0087&rsqb;</number> 3.1. Coefficient of permeability of compound A, introduced in Hank&apos;s medium, in solution in DMSO </paragraph>
<paragraph id="P-0088" lvl="2"><number>&lsqb;0088&rsqb;</number> P&equals;96.10<highlight><superscript>&minus;7 </superscript></highlight>cm/s </paragraph>
<paragraph id="P-0089" lvl="0"><number>&lsqb;0089&rsqb;</number> The permeability of compound A measured in this way in solution (in DMSO) indicates an intrinsic characteristic of this compound. This result indicates the very good ability of compound A to pass through the epithelium when it is in solution. </paragraph>
<paragraph id="P-0090" lvl="0"><number>&lsqb;0090&rsqb;</number> 3.2. Relative rate of intestinal transepithelial passage of compound A </paragraph>
<paragraph id="P-0091" lvl="0"><number>&lsqb;0091&rsqb;</number> The rate of passage of compound A in formulation X was measured and compared with that of compound A in suspension.  
<table-cwu id="TABLE-US-00010">
<number>10</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="OFFSET" colwidth="14PT" align="left"/>
<colspec colname="1" colwidth="133PT" align="left"/>
<colspec colname="2" colwidth="70PT" align="center"/>
<thead>
<row>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry>Formulation X</entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>compound A</entry>
<entry>30 mg</entry>
</row>
<row>
<entry></entry>
<entry>modified corn starch</entry>
<entry>51 mg</entry>
</row>
<row>
<entry></entry>
<entry>200 mesh lactose monohydrate</entry>
<entry>83 mg</entry>
</row>
<row>
<entry></entry>
<entry>povidone K 30</entry>
<entry>4.3 mg&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>sodium laurylsulfate</entry>
<entry>0.17 mg&ensp;&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>8.5 mg&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>1.7 mg&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry>Gelatin capsule</entry>
<entry>178.67 mg&emsp;&ensp;&thinsp;</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="140PT" align="left"/>
<colspec colname="2" colwidth="77PT" align="center"/>
<tbody valign="top">
<row>
<entry>Formulation of compound A</entry>
<entry>Relative rate of passage</entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry>Compound A in suspension in Hank&apos;s medium</entry>
<entry>1</entry>
</row>
<row>
<entry>Compound A formulated in X</entry>
<entry>7</entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</summary-of-invention>
<detailed-description>
<section>
<heading lvl="1">EXAMPLE 1 </heading>
<paragraph id="P-0092" lvl="7"><number>&lsqb;0092&rsqb;</number> 1 mg Gelatin Capsule </paragraph>
<paragraph id="P-0093" lvl="0"><number>&lsqb;0093&rsqb;</number> A gelatin capsule prepared by wet granulation and having the following composition:  
<table-cwu id="TABLE-US-00011">
<number>11</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="175PT" align="left"/>
<colspec colname="2" colwidth="28PT" align="right"/>
<colspec colname="3" colwidth="14PT" align="left"/>
<thead>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Internal phase</entry>
<entry></entry>
<entry></entry>
</row>
<row>
<entry>micronized compound A</entry>
<entry>1</entry>
<entry>mg</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>51</entry>
<entry>mg</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>103.33</entry>
<entry>mg</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>4.3</entry>
<entry>mg</entry>
</row>
<row>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>8.5</entry>
<entry>mg</entry>
</row>
<row>
<entry>Granulation</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry>0.17</entry>
<entry>mg</entry>
</row>
<row>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>1.7</entry>
<entry>mg</entry>
</row>
<row>
<entry>For a size 3 white-opaque gelatin capsule completed up to</entry>
<entry>170</entry>
<entry>mg</entry>
</row>
<row><entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">EXAMPLE 2 </heading>
<paragraph id="P-0094" lvl="7"><number>&lsqb;0094&rsqb;</number> 10 mg Gelatin Capsule </paragraph>
<paragraph id="P-0095" lvl="0"><number>&lsqb;0095&rsqb;</number> A gelatin capsule prepared by wet granulation and having the following composition:  
<table-cwu id="TABLE-US-00012">
<number>12</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="182PT" align="left"/>
<colspec colname="2" colwidth="35PT" align="center"/>
<thead>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Internal phase</entry>
<entry></entry>
</row>
<row>
<entry>micronized compound A</entry>
<entry>&emsp;&thinsp;10 mg</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>&emsp;&thinsp;51 mg</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>94.33 mg</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>&emsp;4.3 mg</entry>
</row>
<row>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>&emsp;8.5 mg</entry>
</row>
<row>
<entry>Granulation</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry>&ensp;0.17 mg</entry>
</row>
<row>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>&ensp;1.7 mg</entry>
</row>
<row>
<entry>For a size 3 white-opaque gelatin capsule completed up to</entry>
<entry>&ensp;&thinsp;170 mg</entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">Example 3: 30 mg Gelatin Capsule </heading>
<paragraph id="P-0096" lvl="0"><number>&lsqb;0096&rsqb;</number> A gelatin capsule prepared by wet granulation and having the following composition:  
<table-cwu id="TABLE-US-00013">
<number>13</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="182PT" align="left"/>
<colspec colname="2" colwidth="35PT" align="center"/>
<thead>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Internal phase</entry>
<entry></entry>
</row>
<row>
<entry>micronized compound A</entry>
<entry>&emsp;&thinsp;30 mg</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>&emsp;&thinsp;51 mg</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>74.33 mg</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>&emsp;4.3 mg</entry>
</row>
<row>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>&emsp;8.5 mg</entry>
</row>
<row>
<entry>Granulation</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry>&ensp;0.17 mg</entry>
</row>
<row>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>&emsp;1.7 mg</entry>
</row>
<row>
<entry>For a size 3 white-opaque gelatin capsule completed up to</entry>
<entry>&ensp;&thinsp;170 mg</entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
<section>
<heading lvl="1">Example 4: 30 mg Gelatin Capsule </heading>
<paragraph id="P-0097" lvl="0"><number>&lsqb;0097&rsqb;</number> A gelatin capsule prepared by wet granulation and having the following composition:  
<table-cwu id="TABLE-US-00014">
<number>14</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="175PT" align="left"/>
<colspec colname="2" colwidth="42PT" align="center"/>
<thead>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Internal phase</entry>
<entry></entry>
</row>
<row>
<entry>micronized compound A</entry>
<entry>&emsp;&thinsp;30 mg</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>&emsp;&thinsp;51 mg</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>73.65 mg</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>&emsp;4.3 mg</entry>
</row>
<row>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>&emsp;8.5 mg</entry>
</row>
<row>
<entry>Granulation</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry>&ensp;0.85 mg</entry>
</row>
<row>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>&emsp;1.7 mg</entry>
</row>
<row>
<entry>For a size 3 white-opaque gelatin capsule completed up to</entry>
<entry>&ensp;&thinsp;170 mg</entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0098" lvl="0"><number>&lsqb;0098&rsqb;</number>  
<table-cwu id="TABLE-US-00015">
<number>15</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">EXAMPLE 5</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>1 mg tablet</entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="OFFSET" colwidth="21PT" align="left"/>
<colspec colname="1" colwidth="154PT" align="left"/>
<colspec colname="2" colwidth="42PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>Internal phase</entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>micronized compound A</entry>
<entry>&emsp;1 mg</entry>
</row>
<row>
<entry></entry>
<entry>corn starch</entry>
<entry>&ensp;50 mg</entry>
</row>
<row>
<entry></entry>
<entry>200 mesh lactose monohydrate</entry>
<entry>130 mg</entry>
</row>
<row>
<entry></entry>
<entry>6 cP hydroxypropyl methyl cellulose</entry>
<entry>&emsp;6 mg</entry>
</row>
<row>
<entry></entry>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>&ensp;10 mg</entry>
</row>
<row>
<entry></entry>
<entry>Granulation</entry>
</row>
<row>
<entry></entry>
<entry>sodium laurylsulfate</entry>
<entry>&emsp;1 mg</entry>
</row>
<row>
<entry></entry>
<entry>purified water</entry>
<entry>&emsp;QS</entry>
</row>
<row>
<entry></entry>
<entry>External phase</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>&emsp;2 mg</entry>
</row>
<row>
<entry></entry>
<entry>For a tablet completed up to</entry>
<entry>200 mg</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0099" lvl="0"><number>&lsqb;0099&rsqb;</number>  
<table-cwu id="TABLE-US-00016">
<number>16</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">EXAMPLE 6</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>10 mg tablet</entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="OFFSET" colwidth="21PT" align="left"/>
<colspec colname="1" colwidth="112PT" align="left"/>
<colspec colname="2" colwidth="49PT" align="right"/>
<colspec colname="3" colwidth="35PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>Internal phase</entry>
<entry></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>micronized compound A</entry>
<entry>10</entry>
<entry>mg</entry>
</row>
<row>
<entry></entry>
<entry>corn starch</entry>
<entry>50</entry>
<entry>mg</entry>
</row>
<row>
<entry></entry>
<entry>200 mesh lactose monohydrate</entry>
<entry>211.5</entry>
<entry>mg</entry>
</row>
<row>
<entry></entry>
<entry>6 cP hydroxypropyl methyl cellulose</entry>
<entry>9</entry>
<entry>mg</entry>
</row>
<row>
<entry></entry>
<entry>sodium carboxymethyl starch</entry>
<entry>15</entry>
<entry>mg</entry>
</row>
<row>
<entry></entry>
<entry>sodium laurylsulfate</entry>
<entry>1.5</entry>
<entry>mg</entry>
</row>
<row>
<entry></entry>
<entry>Granulation</entry>
</row>
<row>
<entry></entry>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry></entry>
<entry>External phase</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>3</entry>
<entry>mg</entry>
</row>
<row>
<entry></entry>
<entry>For a tablet completed up to</entry>
<entry>300</entry>
<entry>mg</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
<paragraph id="P-0100" lvl="0"><number>&lsqb;0100&rsqb;</number>  
<table-cwu id="TABLE-US-00017">
<number>17</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217PT" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" align="center">EXAMPLE 7</entry>
</row>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry>30 mg tablet</entry>
</row>
<row><entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="OFFSET" colwidth="21PT" align="left"/>
<colspec colname="1" colwidth="154PT" align="left"/>
<colspec colname="2" colwidth="42PT" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry>Internal phase</entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry>micronized compound A</entry>
<entry>&ensp;30 mg</entry>
</row>
<row>
<entry></entry>
<entry>corn starch</entry>
<entry>&ensp;80 mg</entry>
</row>
<row>
<entry></entry>
<entry>200 mesh lactose monohydrate</entry>
<entry>252 mg</entry>
</row>
<row>
<entry></entry>
<entry>povidone K 30</entry>
<entry>&ensp;12 mg</entry>
</row>
<row>
<entry></entry>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>&ensp;20 mg</entry>
</row>
<row>
<entry></entry>
<entry>sodium laurylsulfate</entry>
<entry>&emsp;2 mg</entry>
</row>
<row>
<entry></entry>
<entry>Granulation</entry>
</row>
<row>
<entry></entry>
<entry>purified water</entry>
<entry>QS</entry>
</row>
<row>
<entry></entry>
<entry>External phase</entry>
</row>
<row>
<entry></entry>
<entry>magnesium stearate</entry>
<entry>&emsp;4 mg</entry>
</row>
<row>
<entry></entry>
<entry>For a tablet completed up to</entry>
<entry>400 mg</entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</paragraph>
</section>
</detailed-description>
</subdoc-description>
<subdoc-claims>
<claim id="CLM-00001">
<claim-text><highlight><bold>1</bold></highlight>. A pharmaceutical composition for the oral administration of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide of the formula </claim-text>
<claim-text> 
<chemistry-cwu id="CHEM-US-00002">
<number>2</number>
<image id="EMI-C00002" he="116.88705" wi="168.99435" file="US20030003145A1-20030102-C00002.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00002" file="US20030003145A1-20030102-C00002.CDX"/>
<chemistry-mol-file id="CHEMMOL-00002" file="US20030003145A1-20030102-C00002.MOL"/>
</chemistry-cwu>
</claim-text>
<claim-text>one of its pharmaceutically acceptable salts or one of their solvates (active principle hereafter), comprising: 
<claim-text>0.5% to 20% by weight of active principle in micronized form, </claim-text>
<claim-text>0.05% to 0.5% by weight of a sodium alkylsulfate, </claim-text>
<claim-text>2.5% to 10% by weight of disintegrating agent, </claim-text>
<claim-text>and pharmaceutical excipients, said composition being formulated by wet granulation. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00002">
<claim-text><highlight><bold>2</bold></highlight>. A pharmaceutical composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> which comprises: 
<claim-text>0.5% to 20% by weight of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide in micronized form, </claim-text>
<claim-text>0.05% to 0.5% by weight of sodium laurylsulfate, and </claim-text>
<claim-text>2.5% to 10% by weight of crosslinked sodium carboxymethyl cellulose. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00003">
<claim-text><highlight><bold>3</bold></highlight>. A pharmaceutical composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> which contains: 
<claim-text>0.5% to 20% by weight of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide in micronized form, </claim-text>
<claim-text>0.1% by weight of sodium laurylsulfate, </claim-text>
<claim-text>5% by weight of crosslinked sodium carboxymethyl cellulose, </claim-text>
<claim-text>1% to 10% by weight of binder, </claim-text>
<claim-text>0.2% to 5% by weight of lubricant, </claim-text>
<claim-text>and a diluent in a sufficient amount for 100%. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00004">
<claim-text><highlight><bold>4</bold></highlight>. A pharmaceutical composition according to any one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00003">3</dependent-claim-reference> wherein the sodium alkylsulfate is added to the purified water for wet granulation. </claim-text>
</claim>
<claim id="CLM-00005">
<claim-text><highlight><bold>5</bold></highlight>. A pharmaceutical composition according to any one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00004">4</dependent-claim-reference> in the form of gelatin capsules, tablets, sachets or powders. </claim-text>
</claim>
<claim id="CLM-00006">
<claim-text><highlight><bold>6</bold></highlight>. A pharmaceutical composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> in the form of a gelatin capsule and having the following formulation, expressed in percentages by weight: </claim-text>
<claim-text>Internal phase </claim-text>
<claim-text> 
<table-cwu id="TABLE-US-00018">
<number>18</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="182PT" align="left"/>
<colspec colname="2" colwidth="35PT" align="right"/>
<thead>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Internal phase</entry>
<entry></entry>
</row>
<row>
<entry>N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-</entry>
<entry>0.59%</entry>
</row>
<row>
<entry>4-methylpyrazole-3-carboxamide in micronized form</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>30%</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>60.78%</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>2.53%</entry>
</row>
<row>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>5%</entry>
</row>
<row>
<entry>Granulation</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry>0.1%</entry>
</row>
<row>
<entry>water</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>1%</entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</claim-text>
</claim>
<claim id="CLM-00007">
<claim-text><highlight><bold>7</bold></highlight>. A pharmaceutical composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> in the form of a gelatin capsule and having the following formulation, expressed in percentages by weight: </claim-text>
<claim-text>Internal phase </claim-text>
<claim-text> 
<table-cwu id="TABLE-US-00019">
<number>19</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="182PT" align="left"/>
<colspec colname="2" colwidth="35PT" align="right"/>
<thead>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Internal phase</entry>
<entry></entry>
</row>
<row>
<entry>N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl-</entry>
<entry>5.88%</entry>
</row>
<row>
<entry>4-methylpyrazole-3-carboxamide in micronized form</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>30%</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>55.49%</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>2.53%</entry>
</row>
<row>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>5%</entry>
</row>
<row>
<entry>Granulation</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry>0.1%</entry>
</row>
<row>
<entry>water</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>1%</entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</claim-text>
</claim>
<claim id="CLM-00008">
<claim-text><highlight><bold>8</bold></highlight>. A pharmaceutical composition according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> in the form of a gelatin capsule and having the following formulation, expressed in percentages by weight: </claim-text>
<claim-text>Internal phase </claim-text>
<claim-text> 
<table-cwu id="TABLE-US-00020">
<number>20</number>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="182PT" align="left"/>
<colspec colname="2" colwidth="35PT" align="right"/>
<thead>
<row>
<entry></entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry>Internal phase</entry>
<entry></entry>
</row>
<row>
<entry>N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-</entry>
<entry>17.64%</entry>
</row>
<row>
<entry>4-methylpyrazole-3-carboxamide in micronized form</entry>
</row>
<row>
<entry>corn starch</entry>
<entry>30%</entry>
</row>
<row>
<entry>200 mesh lactose monohydrate</entry>
<entry>43.73%</entry>
</row>
<row>
<entry>povidone K 30</entry>
<entry>2.53%</entry>
</row>
<row>
<entry>crosslinked sodium carboxymethyl cellulose</entry>
<entry>5%</entry>
</row>
<row>
<entry>Granulation</entry>
</row>
<row>
<entry>sodium laurylsulfate</entry>
<entry>0.1%</entry>
</row>
<row>
<entry>water</entry>
<entry>QS</entry>
</row>
<row>
<entry>External phase</entry>
</row>
<row>
<entry>magnesium stearate</entry>
<entry>1%</entry>
</row>
<row><entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
</row>
</tbody>
</tgroup>
</table>
</table-cwu>
</claim-text>
</claim>
<claim id="CLM-00009">
<claim-text><highlight><bold>9</bold></highlight>. A process for the preparation of a pharmaceutical composition according to any one of <dependent-claim-reference depends_on="CLM-00001">claims 1</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00005">5</dependent-claim-reference>, characterised in that: 
<claim-text>a) the active principle, the disintegrating agent and the sodium alkylsulfate are mixed at room temperature with a diluent, a binder and, optionally, a coloring agent; </claim-text>
<claim-text>b) the mixture is wetted with purified water; </claim-text>
<claim-text>c) the resulting wet mass is dried and graded; and </claim-text>
<claim-text>d) a lubricant and, optionally, an antiadhesive, a flowing agent, a coloring agent and/or a flavoring agent are added to the resulting graded dry grains. </claim-text>
</claim-text>
</claim>
<claim id="CLM-00010">
<claim-text><highlight><bold>10</bold></highlight>. A process according to <dependent-claim-reference depends_on="CLM-00009">claim 9</dependent-claim-reference> for the preparation of a pharmaceutical composition according to one of <dependent-claim-reference depends_on="CLM-00006">claims 6</dependent-claim-reference> to <dependent-claim-reference depends_on="CLM-00008">8</dependent-claim-reference>, characterised in that the sodium alkylsulfate is incorporated in step b).</claim-text>
</claim>
</subdoc-claims>
</patent-application-publication>
